NFKB1 and lymphedema: Li et al. reported that type II arabinogalactan (CAPW-1) could activate the TLR4/NF-κB/VEGF-C signaling pathway in LECs to promote lymphatic angiogenesis and reduce edema in mice with secondary lymphedema (Li et al., 2024).